OKYO PHARMA LTD

Insider option holdings show OKYO Pharma’s leadership is “holding for the long‑term,” backing pre‑clinical milestones while keeping an eye on dilution risk.

Insider holdings show a director’s steady 20%‑upward stake in OKYO Pharma, signalling confidence in its pre‑clinical biotech prospects and potential for future rallies.

OKYO Pharma’s insider holdings reveal executive confidence in eye‑disease drugs, sparking investor buzz amid a flat share price—could this signal a future rally?